Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A brief dose escalation followed by a phase 2 study of RAD001 [everolimus] in combination with trastuzumab in HER2-positive metastatic breast cancer

Trial Profile

A brief dose escalation followed by a phase 2 study of RAD001 [everolimus] in combination with trastuzumab in HER2-positive metastatic breast cancer

Completed
Phase of Trial: Phase I/II

Latest Information Update: 12 Mar 2016

At a glance

  • Drugs Everolimus (Primary) ; Trastuzumab
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 09 Mar 2016 According to ClinicalTrials.gov record, Time frame for primary endpoint changed from 2 years to 21 days.
    • 09 Mar 2016 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top